Castro Domínguez Francisco
Les teràpies biològiques i cel·lulars són una opció de tractament per a diverses malalties reumàtiques, incloent l'artritis reumatoide, l'espondilitis anquilosant i la psoriasi.
Les teràpies biològiques impliquen l'ús de proteïnes produïdes pel cos humà o per enginyeria genètica per bloquejar o reduir l'acció dels mediadors inflamatoris al cos. Aquestes proteïnes poden incloure anticossos monoclonals, receptors de cèl·lules T modificats i molècules de fusió de proteïnes. Les teràpies biològiques poden ajudar a reduir la inflamació, millorar la funció articular i prevenir la progressió de la malaltia.
Adalimumab is a biologic drug belonging to the class of tumor necrosis factor-alpha (TNF-α) inhibitors. In rheumatology, it is primarily used for the treatment of various autoimmune and autoinflammatory diseases, particularly in cases where there is a component of chronic inflammation mediated by TNF-α.
Etanercept is a biologic drug that acts as a soluble TNF receptor fusion protein. It binds to TNF-alpha and prevents it from interacting with cell surface TNF receptors, thereby inhibiting the biological activity of TNF-alpha. In rheumatology, etanercept is primarily used for the treatment of various autoimmune and inflammatory conditions where TNF-alpha plays a central role in disease pathogenesis.
Golimumab is a biologic drug that belongs to the class of tumor necrosis factor-alpha (TNF-α) inhibitors. It works by binding to soluble and membrane-bound TNF-α, thereby inhibiting its interaction with TNF receptors and reducing inflammation. In rheumatology, golimumab is primarily used for the treatment of various autoimmune and inflammatory diseases where TNF-α plays a pivotal role in the disease process.
Tofacitinib is a small molecule Janus kinase (JAK) inhibitor that modulates intracellular signaling pathways involved in the inflammatory process. In rheumatology, tofacitinib is primarily used for the treatment of autoimmune diseases, particularly those involving chronic inflammation and joint damage.
Baricitinib is a small molecule Janus kinase (JAK) inhibitor that works by selectively inhibiting JAK1 and JAK2, key enzymes involved in the signaling pathways of multiple cytokines implicated in the pathogenesis of autoimmune diseases. In rheumatology, baricitinib is primarily used for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have not responded adequately to, or are intolerant of, methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Secukinumab is a fully human monoclonal IgG1/κ antibody that selectively binds and neutralizes a proinflammatory cytokine, interleukin 17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of autoimmune diseases. In rheumatology, secukinumab is primarily used for the treatment of ankylosing spondylitis and psoriatic arthritis, both of which are chronic inflammatory conditions associated with IL-17A-mediated inflammation.
Ixekizumab is an IgG4 type monoclonal antibody that binds with high affinity and specifically to interleukin 17A (both IL-17A and IL-17A/F), a pro-inflammatory cytokine involved in the pathogenesis of autoimmune diseases. In rheumatology, ixekizumab is primarily used for the treatment of psoriatic arthritis, a chronic inflammatory arthritis associated with psoriasis.
Morning | Afternoon | |
---|---|---|
Monday | 08:00 - 14:00 h | 15:00 - 20:00 h |
Tuesday | 08:00 - 14:00 h | 15:00 - 20:00 h |
Wednesday | 08:00 - 14:00 h | 15:00 - 20:00 h |
Thursday | 08:00 - 14:00 h | 15:00 - 20:00 h |
Friday | 08:00 - 14:00 h | 15:00 - 20:00 h |